LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application
Uppsala, Sweden, June 6, 2024. The pharmaceutical company Dicot Pharma AB is developing LIB-01 into a new potency drug with improved properties compared to currently available drugs. New research results on LIB-01 show that the substance appears to influence factors linked to certain metabolic diseases. Based on these research results, the company has submitted a patent application for the treatment of several new indications.
Dicot Pharma is developing the potency drug candidate LIB-01 with the aim of offering a treatment that surpasses current drugs, including a long-term effect on erectile function. Within the framework of research on LIB-01, the company has received new results from animal studies showing that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes and high blood pressure.
The company has today filed a new patent application to seek protection for the treatment of these indications.
Based on these promising results and the currently filed patent application, Dicot's Board of Directors and management will conduct a strategic review during the third quarter of 2024 to determine how these new research results should be taken forward by the company and complement the existing product portfolio in sexual dysfunctions.
"These new findings are highly interesting, and we look forward to realizing the full commercial potential that this could bring. At the same time, we will be careful not to do so at the expense of the current development of LIB-01 for the treatment of erectile dysfunction.", comments Dicot Pharma's CEO Elin Trampe.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 5,500 shareholders. For more information, please visit www.dicotpharma.com.
This disclosure contains information that Dicot Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-06-2024 17:25 CET.